Predictive and prognostic markers are at the forefront of personalised cancer care, offering clinicians the ability to both anticipate a patient’s response to specific therapies and gauge the likely ...

Researchers in Japan have developed a predictive model that could improve treatment decisions for advanced pancreatic cancer patients. By combining tumor marker readings with patients' genetic ...

PITTSBURGH, March 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (POAI), a leader in AI-driven drug discovery, announced today that it has successfully developed predictive models derived from ...

Multi-center investigation of an early detection model utilizing cfDNA fragmentomics for breast cancer screening. Circulating tumor DNA and its correlation with survival in hormone receptor positive ...

Tumors are heterogenous masses of cells that rapidly divide. Many cells have different mutations, functions, and ways to avoid immune cell detection and drive tumor progression. The heterogeneity of ...

DNA levels at baseline and during treatment predict response and progression free survival in advanced breast cancer, ...

Phase II trial of neoadjuvant nivolumab and SOX in resectable gastric/gastroesophageal junction cancer: Therapeutic response and biomarker correlations. This is an ASCO Meeting Abstract from the 2025 ...

Tumor marker blood tests may help inform various aspects of cancer care, including diagnosis, staging, treatment planning, and outlook. However, they’re often not the only diagnostic tests used. If ...

A tumor marker for pancreatic cancer helps healthcare professionals detect, diagnose, or treat it. However, a person can have high tumor marker levels without having cancer. Tumor markers are ...

Predictive Oncology aims to enhance drug discovery using its biobank and AI, following industry trends exemplified by Regeneron's 23andMe acquisition. Predictive Oncology Inc. is leveraging its ...